How many drugs are losing patent protection in 2016?

Drug Landscape tracks 0 marketed drugs with at least one patent expiring in 2016, sourced from FDA Orange Book + USPTO Patent Public Search.

What is a patent cliff?

A patent cliff is the year a major branded drug loses primary patent protection, opening the market to generic or biosimilar entry. Originator revenue typically drops 30–80% within 24 months, depending on the drug class and the strength of secondary patents.

Are these forecasts accurate?

Patent expiry dates are deterministic — they're the listed expiry from the Orange Book or USPTO record. Generic / biosimilar entry timing depends on litigation outcomes, paragraph IV challenges, settlements, and exclusivity periods which can shift the practical "cliff" by months to years.

Last reviewed 2026-05-14 · How we verify

2016 Pharmaceutical Patent Cliff

0 marketed drugs with patents expiring in 2016, joined to sponsor + therapeutic area + drug class. Historical archive. Sourced from FDA Orange Book + USPTO Patent Public Search.

0 drugs 0 patents 0 therapeutic areas Historical

Sponsors most affected (0)

By therapeutic area

No patent expiries tracked for this year.

Subscribe to patent-cliff alerts

Push every new patent expiry into your RSS reader:

Marketed-drug events RSS
All 2016 pharma events (approvals + readouts + patents)

Biosimilar tracker — who's competing for each post-cliff originator
Patent cliff revenue calculator
2016 patent expiries dataset (CSV / JSON)

2016 Pharmaceutical Patent Cliff

Sponsors most affected (0)

By therapeutic area

Subscribe to patent-cliff alerts

Related